Targeting ‘undruggable’ proteins: Frontier collaborates with AbbVie
AbbVie and Frontier will be drugging validated, but previously inaccessible, E3 ligase, immunology and oncology targets. Credit: Shutterstock.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more
